{"protocolSection": {"identificationModule": {"nctId": "NCT00516139", "orgStudyIdInfo": {"id": "LEP105972"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Lamotrigine Extended-Release In Elderly Patients With Epilepsy", "officialTitle": "Lamotrigine Extended-Release in Elderly Patients With Epilepsy"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-08"}, "primaryCompletionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-08-13", "studyFirstSubmitQcDate": "2007-08-13", "studyFirstPostDateStruct": {"date": "2007-08-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-07-15", "resultsFirstSubmitQcDate": "2011-12-08", "resultsFirstPostDateStruct": {"date": "2012-01-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-30", "lastUpdatePostDateStruct": {"date": "2017-01-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing."}, "conditionsModule": {"conditions": ["Epilepsy"], "keywords": ["Epilepsy elderly seizure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 122, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lamotrigine", "type": "EXPERIMENTAL", "description": "Open-label lamotrigine", "interventionNames": ["Drug: Lamotrigine"]}], "interventions": [{"type": "DRUG", "name": "Lamotrigine", "description": "Open-label", "armGroupLabels": ["Lamotrigine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event", "description": "An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.", "timeFrame": "From Baseline (Week 0) until 3 weeks after the end of treatment (Week 30 or 33)"}], "secondaryOutcomes": [{"measure": "Percent Change From Baseline (BL) in Weekly Seizure (sz.) Frequency for All Partial Seizures During Each Phase of the Study", "description": "Partial-onset sz. have a focal site of onset; sz. activity is initially limited to 1 brain hemisphere. Partial sz. can remain simple or complex, or evolve to generalized tonic-clonic sz. Participants (par.) recorded the number of sz., by type as well as the episode duration of innumerable sz. activity), in daily diaries. If par. withdrew from study, data were averaged for the study portion the par. completed up to the time of drug discontinuation. Percent change from BL = (BL value minus study phase value divided by BL value) x 100; positive values indicate reduction from BL in sz. frequency.", "timeFrame": "Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (Week 30 or 33)"}, {"measure": "Number of Participants With the Indicated Change From Baseline in Weekly Seizure Frequency During Each Phase of the Study", "description": "Participants recorded the number of seizures, by seizure type, as well as the duration of episodes of innumerable seizure activity in their daily diaries during all phases of the study. For participants who withdrew from the study, seizure data were averaged for the portion of the study the participant completed up to the time of study drug discontinuation. Participants who experienced a change from Baseline in the weekly seizure frequency were categorized as having a \\>=25%, \\>=50%, \\>=75%, or 100% reduction or a \\>=50% increase in percent change from Baseline in weekly seizure frequency.", "timeFrame": "Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization (Adj O) Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (ET, Week 30 or 33)"}, {"measure": "Number of Seizure-free Participants at Baseline Who Remained Seizure-free Throughout the Entire Treatment Period", "description": "Participants were considered to be seizure-free if they did not report any seizures at Baseline.", "timeFrame": "Week 30 or 33"}, {"measure": "Number of Participants With Changes From Baseline in Seizure Severity in the Indicated Categories, as Measured by the Investigator's Global Evaluation (IGE) Scale", "description": "Investigators rated the participants' seizure severity at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.", "timeFrame": "Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])"}, {"measure": "Number of Participants With Changes From Baseline in Overall Clinical Status in the Indicated Categories, as Measured by the IGE Scale", "description": "Investigators rated the participants' overall clinical status at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.", "timeFrame": "Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])"}, {"measure": "Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points in the Study", "description": "Change from Baseline was calculated by subtracting the values of systolic and diastolic blood pressures recorded by the investigator at the indicated time points in the study from the respective Baseline values.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])"}, {"measure": "Change From Baseline in the Height at the Indicated Time Points in the Study", "description": "Change from Baseline was calculated by subtracting the value of height measured by the investigator at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])"}, {"measure": "Change From Baseline in the Weight at the Indicated Time Points in the Study", "description": "Change from Baseline was calculated by subtracting the value of weight measured by the investigator at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])"}, {"measure": "Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of basophil, eosinophil, hemoglobin, lymphocyte, monocyte, ANC, platelet count, and WBC count at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Percent Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count, Platelet Count, and White Blood Cell Count at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Percent change from Baseline = (value at each indicated time point in the study minus respective Baseline value divided by Baseline value) x 100.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Change From Baseline in the Mean Corpuscle Hemoglobin Concentration (MCHC), Albumin, and Total Protein at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the values of MCHC, albumin, and total protein at the indicated time points in the study from the respective Baseline values.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCH at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points in the the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCV at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of RBC count at the indicated time points in the study from the Baseline value. Change from baseline is measured as the number of red blood cells x 10\\^12 per liter.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Change From Baseline in Alkaline Phosphatase (Alk P), Alanine Amino Transferase (Ala AT), and Aspartate Amino Transferase (Asp AT) at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of Alk P, Ala AT, and Asp AT at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Change From Baseline in Direct Bilirubin (DB), Total Bilirubin (TB), and Creatinine at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of DB, TB, and creatinine at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Change From Baseline in Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Glucose, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of cholesterol, HDL cholesterol, LDL cholesterol, glucose, potassium, sodium, triglycerides, and urea/BUN at the indicated time points in the study from the Baseline value.", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)"}, {"measure": "Serum LTG Concentrations at Different LTG Doses Based on the Concomitant AED Groups: Neutral (Without Known Enzyme-inducing AED [EIAED], Valproate [VPA]) With EIAED, and With VPA", "description": "The blood samples were collected at the specified study visits; however, serum LTG concentrations were summarized by dose regimen, not by study week. The serum was assayed for LTG using an approved method under the management of Worldwide Bioanalysis, GlaxoSmithKline.", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28"}, {"measure": "Apparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA", "description": "Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. Clearance is defined as the volume of LTG per unit time eliminated from serum. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to Clinical Pharmacokinetics Modelling and Simulation, Clinical Pharmacology, and Discovery Medicine (CPDM) by Clinical Data Management as NONMEM compatible .csv files.", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28"}, {"measure": "Apparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA", "description": "Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. V/F is defined as the apparent volume in which a drug is distributed immediately after it has been injected intravenously and equilibrated between plasma and the surrounding tissues. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28"}, {"measure": "Absorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA", "description": "Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. KA is defined as the rate at which a drug enters the body after administration. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Confident diagnosis of epilepsy\n* Currently treated with one or two antiepileptic medications\n* Able to complete a seizure diary\n\nExclusion criteria:\n\n* History of hypersensitivity to lamotrigine\n* Progressive diseases that would interfere with the study objectives", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "65 Years", "stdAges": ["OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35294-0021", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Gilbert", "state": "Arizona", "zip": "85234", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "GSK Investigational Site", "city": "Litchfield Park", "state": "Arizona", "zip": "85340", "country": "United States", "geoPoint": {"lat": 33.49337, "lon": -112.35794}}, {"facility": "GSK Investigational Site", "city": "Phoenix", "state": "Arizona", "zip": "85003", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "GSK Investigational Site", "city": "Phoenix", "state": "Arizona", "zip": "85013", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "GSK Investigational Site", "city": "Fresno", "state": "California", "zip": "93710", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "GSK Investigational Site", "city": "Fullteron", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "GSK Investigational Site", "city": "Irvine", "state": "California", "zip": "92618", "country": "United States", "geoPoint": {"lat": 33.66946, "lon": -117.82311}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90073", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Pasadena", "state": "California", "zip": "91106", "country": "United States", "geoPoint": {"lat": 34.14778, "lon": -118.14452}}, {"facility": "GSK Investigational Site", "city": "Fort Collins", "state": "Colorado", "zip": "80524", "country": "United States", "geoPoint": {"lat": 40.58526, "lon": -105.08442}}, {"facility": "GSK Investigational Site", "city": "Newark", "state": "Delaware", "zip": "19713", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "GSK Investigational Site", "city": "Gainesville", "state": "Florida", "zip": "32610", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "GSK Investigational Site", "city": "Jacksonville", "state": "Florida", "zip": "32224", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "GSK Investigational Site", "city": "Jacksonville", "state": "Florida", "zip": "32266", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "GSK Investigational Site", "city": "Melbourne", "state": "Florida", "zip": "32901", "country": "United States", "geoPoint": {"lat": 28.08363, "lon": -80.60811}}, {"facility": "GSK Investigational Site", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "GSK Investigational Site", "city": "Ponte Vedra Beach", "state": "Florida", "zip": "32082", "country": "United States", "geoPoint": {"lat": 30.23969, "lon": -81.38564}}, {"facility": "GSK Investigational Site", "city": "Sarasota", "state": "Florida", "zip": "34233", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "GSK Investigational Site", "city": "Atlanta", "state": "Georgia", "zip": "30309", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "GSK Investigational Site", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "GSK Investigational Site", "city": "Suwanee", "state": "Georgia", "zip": "30024", "country": "United States", "geoPoint": {"lat": 34.05149, "lon": -84.0713}}, {"facility": "GSK Investigational Site", "city": "Boise", "state": "Idaho", "zip": "83702", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "GSK Investigational Site", "city": "Springfield", "state": "Illinois", "zip": "62702", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "GSK Investigational Site", "city": "Fort Wayne", "state": "Indiana", "zip": "46805", "country": "United States", "geoPoint": {"lat": 41.1306, "lon": -85.12886}}, {"facility": "GSK Investigational Site", "city": "Indianapolis", "state": "Indiana", "zip": "46256", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "GSK Investigational Site", "city": "Wichita", "state": "Kansas", "zip": "67214", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "GSK Investigational Site", "city": "Louisville", "state": "Kentucky", "zip": "40202", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "GSK Investigational Site", "city": "Scarborough", "state": "Maine", "zip": "4074", "country": "United States", "geoPoint": {"lat": 43.57814, "lon": -70.32172}}, {"facility": "GSK Investigational Site", "city": "Burlington", "state": "Massachusetts", "zip": "01805", "country": "United States", "geoPoint": {"lat": 42.50482, "lon": -71.19561}}, {"facility": "GSK Investigational Site", "city": "Hopedale", "state": "Massachusetts", "zip": "01747", "country": "United States", "geoPoint": {"lat": 42.13065, "lon": -71.54117}}, {"facility": "GSK Investigational Site", "city": "Traverse City", "state": "Michigan", "zip": "49684", "country": "United States", "geoPoint": {"lat": 44.76306, "lon": -85.62063}}, {"facility": "GSK Investigational Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55422", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "GSK Investigational Site", "city": "St. Paul", "state": "Minnesota", "zip": "55102", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "GSK Investigational Site", "city": "Chesterfield", "state": "Missouri", "zip": "63017", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"facility": "GSK Investigational Site", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "GSK Investigational Site", "city": "Henderson", "state": "Nevada", "zip": "89014", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "GSK Investigational Site", "city": "Camden", "state": "New Jersey", "zip": "08103", "country": "United States", "geoPoint": {"lat": 39.92595, "lon": -75.11962}}, {"facility": "GSK Investigational Site", "city": "Newark", "state": "New Jersey", "zip": "07103", "country": "United States", "geoPoint": {"lat": 40.73566, "lon": -74.17237}}, {"facility": "GSK Investigational Site", "city": "Summit", "state": "New Jersey", "zip": "07901", "country": "United States", "geoPoint": {"lat": 40.71562, "lon": -74.36468}}, {"facility": "GSK Investigational Site", "city": "Cedarhurst", "state": "New York", "zip": "11516", "country": "United States", "geoPoint": {"lat": 40.62288, "lon": -73.7243}}, {"facility": "GSK Investigational Site", "city": "Rochester", "state": "New York", "zip": "14642", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "GSK Investigational Site", "city": "Schenectady", "state": "New York", "zip": "12308", "country": "United States", "geoPoint": {"lat": 42.81424, "lon": -73.93957}}, {"facility": "GSK Investigational Site", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "GSK Investigational Site", "city": "Toledo", "state": "Ohio", "zip": "43614", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19102", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "GSK Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "GSK Investigational Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15240", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "GSK Investigational Site", "city": "Sellersville", "state": "Pennsylvania", "zip": "18960", "country": "United States", "geoPoint": {"lat": 40.35399, "lon": -75.3049}}, {"facility": "GSK Investigational Site", "city": "Columbia", "state": "Tennessee", "zip": "38401", "country": "United States", "geoPoint": {"lat": 35.61507, "lon": -87.03528}}, {"facility": "GSK Investigational Site", "city": "Cordova", "state": "Tennessee", "zip": "38018", "country": "United States", "geoPoint": {"lat": 35.15565, "lon": -89.7762}}, {"facility": "GSK Investigational Site", "city": "Germantown", "state": "Tennessee", "zip": "38139", "country": "United States", "geoPoint": {"lat": 35.08676, "lon": -89.81009}}, {"facility": "GSK Investigational Site", "city": "Nashville", "state": "Tennessee", "zip": "37232", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75214", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "GSK Investigational Site", "city": "Temple", "state": "Texas", "zip": "76508", "country": "United States", "geoPoint": {"lat": 31.09823, "lon": -97.34278}}, {"facility": "GSK Investigational Site", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "GSK Investigational Site", "city": "Bremerton", "state": "Washington", "zip": "98310", "country": "United States", "geoPoint": {"lat": 47.56732, "lon": -122.63264}}, {"facility": "GSK Investigational Site", "city": "Madison", "state": "Wisconsin", "zip": "53715", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "GSK Investigational Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53215", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "GSK Investigational Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53226", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "LEP105972", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LEP105972", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LEP105972", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LEP105972", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LEP105972", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LEP105972", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LEP105972", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study consisted of 4 phases (Ph): 7-week (w) Dose-escalation Ph, 8-w Adjunctive Maintenance (AM) Ph, 13-w Adj. Optimization (AO) Ph or 13-w Conversion/Monotherapy (C/M) Ph, and a 2-5 w Taper/Follow up (T/F) Ph.", "groups": [{"id": "FG000", "title": "Lamotrigine (LTG)-Extended Release (XR) Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "122"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Study completers completed Escalation, AM, and either AO or both Conversion and Monotherapy Phases.", "numSubjects": "84"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "27"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "121"}]}], "measures": [{"title": "Age, Continuous", "description": "Baseline characteristics were collected for the Safety Population, which included all participants who were enrolled and took at least one dose of the study drug. One participant enrolled in the study did not take at least one dose of the study drug.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "72.5", "spread": "5.53"}]}]}]}, {"title": "Gender", "description": "Baseline characteristics were collected for the Safety Population, which included all participants who were enrolled and took at least one dose of the study drug. One participant enrolled in the study did not take at least one dose of the study drug.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "59"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "62"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Baseline characteristics were collected for the Safety Population, which included all participants who were enrolled and took at least one dose of the study drug. One participant enrolled in the study did not take at least one dose of the study drug. Participants are allowed to select more than one race.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "105"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event", "description": "An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.", "populationDescription": "Safety Population: all participants who were enrolled and took at least one dose of study drug", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From Baseline (Week 0) until 3 weeks after the end of treatment (Week 30 or 33)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}]}], "classes": [{"title": "Participants with any SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}]}]}, {"title": "Participants with any non-serious AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "112"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline (BL) in Weekly Seizure (sz.) Frequency for All Partial Seizures During Each Phase of the Study", "description": "Partial-onset sz. have a focal site of onset; sz. activity is initially limited to 1 brain hemisphere. Partial sz. can remain simple or complex, or evolve to generalized tonic-clonic sz. Participants (par.) recorded the number of sz., by type as well as the episode duration of innumerable sz. activity), in daily diaries. If par. withdrew from study, data were averaged for the study portion the par. completed up to the time of drug discontinuation. Percent change from BL = (BL value minus study phase value divided by BL value) x 100; positive values indicate reduction from BL in sz. frequency.", "populationDescription": "Safety Population. Only those participants who had seizures at baseline were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Percent change in seizure frequency", "timeFrame": "Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (Week 30 or 33)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}]}], "classes": [{"title": "Dose-Escalation Phase (Week 7), n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "97.8", "lowerLimit": "-146.3", "upperLimit": "100.0"}]}]}, {"title": "Maintenance Phase (Week 15), n=43", "categories": [{"measurements": [{"groupId": "OG000", "value": "100.0", "lowerLimit": "-162.5", "upperLimit": "100.0"}]}]}, {"title": "Adjunctive Optimization Phase (Week 28), n=15", "categories": [{"measurements": [{"groupId": "OG000", "value": "100.0", "lowerLimit": "33.3", "upperLimit": "100.0"}]}]}, {"title": "Conversion Phase (Week 20), n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "100.0", "lowerLimit": "-44.5", "upperLimit": "100.0"}]}]}, {"title": "Monotherapy Phase (Week 28), n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "100.0", "lowerLimit": "-269.8", "upperLimit": "100.0"}]}]}, {"title": "End Of Treatment (Week 30/33), n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "90.4", "lowerLimit": "-86.7", "upperLimit": "100.0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With the Indicated Change From Baseline in Weekly Seizure Frequency During Each Phase of the Study", "description": "Participants recorded the number of seizures, by seizure type, as well as the duration of episodes of innumerable seizure activity in their daily diaries during all phases of the study. For participants who withdrew from the study, seizure data were averaged for the portion of the study the participant completed up to the time of study drug discontinuation. Participants who experienced a change from Baseline in the weekly seizure frequency were categorized as having a \\>=25%, \\>=50%, \\>=75%, or 100% reduction or a \\>=50% increase in percent change from Baseline in weekly seizure frequency.", "populationDescription": "Safety Population. Only those participants who had seizures at baseline were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization (Adj O) Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (ET, Week 30 or 33)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}]}], "classes": [{"title": "Dose-Escalation (Week 7), >=25% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}]}]}, {"title": "Dose-Escalation (Week 7), >=50% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}, {"title": "Dose-Escalation (Week 7), >=75% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}]}]}, {"title": "Dose-Escalation (Week 7), 100% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}]}]}, {"title": "Dose-Escalation (Week 7), >=50% increase, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Maintenance (Week 15), >=25% reduction, n=43", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}]}]}, {"title": "Maintenance (Week 15), >=50% reduction, n=43", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}]}]}, {"title": "Maintenance (Week 15), >=75% reduction, n=43", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}]}]}, {"title": "Maintenance (Week 15), 100% reduction, n=43", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}]}]}, {"title": "Maintenance (Week 15), >=50% increase, n=43", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Adj O (Week 28), >=25% reduction, n=15", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}, {"title": "Adj O (Week 28), >=50% reduction, n=15", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}, {"title": "Adj O (Week 28), >=75% reduction, n=15", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}]}]}, {"title": "Adj O (Week 28), 100% reduction, n=15", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Adj O (Week 28), >=50% increase, n=15", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Conversion (Week 20), >=25% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}, {"title": "Conversion (Week 20), >=50% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}, {"title": "Conversion (Week 20), >=75% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}]}]}, {"title": "Conversion (Week 20), 100% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}]}]}, {"title": "Conversion (Week 20), >=50% increase, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Monotherapy (Week 28), >=25% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}, {"title": "Monotherapy (Week 28), >=50% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}]}]}, {"title": "Monotherapy (Week 28), >=75% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}]}]}, {"title": "Monotherapy (Week 28), 100% reduction, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}, {"title": "Monotherapy (Week 28), >=50% increase, n=24", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "ET (Week 30/33), >=25% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}]}]}, {"title": "ET (Week 30/33), >=50% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}]}]}, {"title": "ET (Week 30/33), >=75% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "ET (Week 30/33), 100% reduction, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}]}]}, {"title": "ET (Week 30/33), >=50% increase, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Seizure-free Participants at Baseline Who Remained Seizure-free Throughout the Entire Treatment Period", "description": "Participants were considered to be seizure-free if they did not report any seizures at Baseline.", "populationDescription": "Safety Population. Participants who were seizure-free at Baseline were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 30 or 33", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}]}], "classes": [{"title": "Remained Seizure-Free", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}]}]}, {"title": "Did Not Remain Seizure-Free", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Changes From Baseline in Seizure Severity in the Indicated Categories, as Measured by the Investigator's Global Evaluation (IGE) Scale", "description": "Investigators rated the participants' seizure severity at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.", "populationDescription": "Safety Population. Only those participants who had seizures at baseline were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}]}], "classes": [{"title": "Week 15, Adj M Phase, Improvement, n=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "Week 15, Adj M Phase, No change, n=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}]}]}, {"title": "Week 15, Adj M Phase, Deterioration, n=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Week 28, Adj O Phase, Improvement, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}, {"title": "Week 28, Adj O Phase, No change, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}, {"title": "Week 28, Adj O Phase, Deterioration, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Week 28, Mono Phase, Improvement, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}, {"title": "Week 28, Mono Phase, No change, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}]}]}, {"title": "Week 28, Mono Phase, Deterioration, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Week 28, WD, Improvement, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}, {"title": "Week 28, WD, No change, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "Week 28, WD, Deterioration, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Changes From Baseline in Overall Clinical Status in the Indicated Categories, as Measured by the IGE Scale", "description": "Investigators rated the participants' overall clinical status at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.", "populationDescription": "Safety Population. Participants with missing data were not analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}]}], "classes": [{"title": "Week 15, Adj M Phase, Improvement, n=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}]}]}, {"title": "Week 15, Adj M Phase, No change, n=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}, {"title": "Week 15, Adj M Phase, Deterioration, n=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Week 28, Adj O Phase, Improvement, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}]}]}, {"title": "Week 28, Adj O Phase, No change, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Week 28, Adj O Phase, Deterioration, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Week 28, Mono Phase, Improvement, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "43"}]}]}, {"title": "Week 28, Mono Phase, No change, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}, {"title": "Week 28, Mono Phase, Deterioration, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "Week 28, WD, Improvement, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}, {"title": "Week 28, WD, No change, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}]}]}, {"title": "Week 28, WD, Deterioration, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points in the Study", "description": "Change from Baseline was calculated by subtracting the values of systolic and diastolic blood pressures recorded by the investigator at the indicated time points in the study from the respective Baseline values.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeters of mercury", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}]}], "classes": [{"title": "Systolic BP, Week 15, Adj M Phase, n=88", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.51", "spread": "19.038"}]}]}, {"title": "Systolic BP, Week 28, Adj O Phase, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.62", "spread": "15.377"}]}]}, {"title": "Systolic BP, Week 28, Mono Phase, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "20.509"}]}]}, {"title": "Systolic BP, Week 28, WD, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.00", "spread": "15.566"}]}]}, {"title": "Systolic BP, Week 30/33, EOS, n=119", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.19", "spread": "15.928"}]}]}, {"title": "Diastolic BP, Week 15, Adj M Phase, n=88", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.22", "spread": "10.547"}]}]}, {"title": "Diastolic BP, Week 28, Adj O Phase, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.05", "spread": "7.214"}]}]}, {"title": "Diastolic BP, Week 28, Mono Phase, n=63", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "10.754"}]}]}, {"title": "Diastolic BP, Week 28, WD, n=35", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.09", "spread": "8.763"}]}]}, {"title": "Diastolic BP, Week 30/33, EOS, n=119", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.07", "spread": "9.102"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Height at the Indicated Time Points in the Study", "description": "Change from Baseline was calculated by subtracting the value of height measured by the investigator at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "centimeters", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}]}], "classes": [{"title": "Week 15, Adj M Phase, n=90", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "1.302"}]}]}, {"title": "Week 28, Adj O Phase, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.29", "spread": "2.217"}]}]}, {"title": "Week 28, Mono Phase, n=62", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "1.293"}]}]}, {"title": "Week 28, WD, n=36", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "1.028"}]}]}, {"title": "Week 30/33, EOS, n=120", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "1.417"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Weight at the Indicated Time Points in the Study", "description": "Change from Baseline was calculated by subtracting the value of weight measured by the investigator at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kilograms", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}]}], "classes": [{"title": "Week 15, Adj M Phase, n=88", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "3.204"}]}]}, {"title": "Week 28, Adj O Phase, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "2.968"}]}]}, {"title": "Week 28, Mono Phase, n=62", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "3.520"}]}]}, {"title": "Week 28, WD, n=36", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.27", "spread": "3.735"}]}]}, {"title": "Week 30/33, EOS, n=119", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "3.470"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of basophil, eosinophil, hemoglobin, lymphocyte, monocyte, ANC, platelet count, and WBC count at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Giga (10^9) cells per liter", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"title": "Basophil, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.03", "upperLimit": "0.06"}]}]}, {"title": "Basophil, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.02", "upperLimit": "0.02"}]}]}, {"title": "Basophil, Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.05", "upperLimit": "0.05"}]}]}, {"title": "Basophil, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.04", "upperLimit": "0.04"}]}]}, {"title": "Eosinophil, Week 15, Adj M, n=89", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.38", "upperLimit": "0.55"}]}]}, {"title": "Eosinophil, Week 28, Adj O, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "lowerLimit": "-0.06", "upperLimit": "0.26"}]}]}, {"title": "Eosinophil, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "lowerLimit": "-0.23", "upperLimit": "0.54"}]}]}, {"title": "Eosinophil, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "lowerLimit": "-0.17", "upperLimit": "0.84"}]}]}, {"title": "Hemoglobin, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.00", "lowerLimit": "-38.00", "upperLimit": "19.00"}]}]}, {"title": "Hemoglobin, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.00", "lowerLimit": "-22.00", "upperLimit": "4.00"}]}]}, {"title": "Hemoglobin, Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.00", "lowerLimit": "-25.00", "upperLimit": "10.00"}]}]}, {"title": "Hemoglobin, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.00", "lowerLimit": "-21.00", "upperLimit": "31.00"}]}]}, {"title": "Lymphocytes, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12", "lowerLimit": "-1.55", "upperLimit": "1.52"}]}]}, {"title": "Lymphocytes, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "lowerLimit": "-0.61", "upperLimit": "0.40"}]}]}, {"title": "Lymphocytes, Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "lowerLimit": "-1.75", "upperLimit": "0.62"}]}]}, {"title": "Lymphocytes, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "lowerLimit": "-0.94", "upperLimit": "0.66"}]}]}, {"title": "Monocytes, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "lowerLimit": "-0.41", "upperLimit": "0.47"}]}]}, {"title": "Monocytes, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.55", "upperLimit": "0.26"}]}]}, {"title": "Monocytes, Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "lowerLimit": "-0.37", "upperLimit": "0.40"}]}]}, {"title": "Monocytes, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "lowerLimit": "-0.48", "upperLimit": "0.64"}]}]}, {"title": "Absolute Neutrophil Count, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "lowerLimit": "-3.00", "upperLimit": "5.04"}]}]}, {"title": "Absolute Neutrophil Count, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "lowerLimit": "-2.17", "upperLimit": "3.31"}]}]}, {"title": "Absolute Neutrophil Count, Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.17", "lowerLimit": "-3.18", "upperLimit": "2.71"}]}]}, {"title": "Absolute Neutrophil Count, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "lowerLimit": "-1.99", "upperLimit": "6.47"}]}]}, {"title": "Platelet Count, Week 15, Adj M, n=84", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.50", "lowerLimit": "-91.00", "upperLimit": "226.00"}]}]}, {"title": "Platelet Count, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.00", "lowerLimit": "-55.00", "upperLimit": "216.00"}]}]}, {"title": "Platelet Count, Week 28, Mono, n=54", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-75.00", "upperLimit": "104.00"}]}]}, {"title": "Platelet Count, Week 28, WD, n=32", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.50", "lowerLimit": "-80.00", "upperLimit": "172.00"}]}]}, {"title": "White Blood Cell Count, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "lowerLimit": "-2.80", "upperLimit": "5.70"}]}]}, {"title": "White Blood Cell Count, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "lowerLimit": "-2.40", "upperLimit": "3.20"}]}]}, {"title": "White Blood Cell Count, Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "lowerLimit": "-3.50", "upperLimit": "2.00"}]}]}, {"title": "White Blood Cell Count, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "lowerLimit": "-2.20", "upperLimit": "6.00"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count, Platelet Count, and White Blood Cell Count at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Percent change from Baseline = (value at each indicated time point in the study minus respective Baseline value divided by Baseline value) x 100.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Percent change in counts", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"title": "Basophil, Week 15, Adj M, n=89", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.80", "upperLimit": "1.00"}]}]}, {"title": "Basophil, Week 28, Adj O, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.50", "upperLimit": "0.50"}]}]}, {"title": "Basophil, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.80", "upperLimit": "0.90"}]}]}, {"title": "Basophil, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.50", "upperLimit": "0.90"}]}]}, {"title": "Eosinophil, Week 15, Adj M, n=89", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "lowerLimit": "-4.40", "upperLimit": "10.90"}]}]}, {"title": "Eosinophil, Week 28, Adj O, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "lowerLimit": "-1.50", "upperLimit": "4.30"}]}]}, {"title": "Eosinophil, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "lowerLimit": "-3.30", "upperLimit": "10.80"}]}]}, {"title": "Eosinophil, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "lowerLimit": "-2.90", "upperLimit": "17.60"}]}]}, {"title": "Hematocrit, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "lowerLimit": "-0.11", "upperLimit": "0.06"}]}]}, {"title": "Hematocrit, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "lowerLimit": "-0.07", "upperLimit": "0.02"}]}]}, {"title": "Hematocrit, Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "lowerLimit": "-0.09", "upperLimit": "0.04"}]}]}, {"title": "Hematocrit, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00", "lowerLimit": "-0.04", "upperLimit": "0.10"}]}]}, {"title": "Lymphocytes, Week 15, Adj M, n=89", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.10", "lowerLimit": "-25.80", "upperLimit": "18.90"}]}]}, {"title": "Lymphocytes, Week 28, Adj O, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.40", "lowerLimit": "-16.00", "upperLimit": "13.60"}]}]}, {"title": "Lymphocytes, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.50", "lowerLimit": "-23.90", "upperLimit": "12.40"}]}]}, {"title": "Lymphocytes, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.60", "lowerLimit": "-14.20", "upperLimit": "8.10"}]}]}, {"title": "Monocytes, Week 15, Adj M, n=89", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-8.90", "upperLimit": "6.50"}]}]}, {"title": "Monocytes, Week 28, Adj O, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "lowerLimit": "-10.90", "upperLimit": "5.10"}]}]}, {"title": "Monocytes, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "lowerLimit": "-6.40", "upperLimit": "9.50"}]}]}, {"title": "Monocytes, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "lowerLimit": "-8.00", "upperLimit": "8.10"}]}]}, {"title": "Total Neutrophils, Week 15, Adj M, n=89", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "lowerLimit": "-26.30", "upperLimit": "30.40"}]}]}, {"title": "Total Neutrophils, Week 28, Adj O, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "lowerLimit": "-13.80", "upperLimit": "16.80"}]}]}, {"title": "Total Neutrophils, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "lowerLimit": "-13.80", "upperLimit": "24.20"}]}]}, {"title": "Total Neutrophils, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.20", "lowerLimit": "-12.00", "upperLimit": "19.20"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Mean Corpuscle Hemoglobin Concentration (MCHC), Albumin, and Total Protein at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the values of MCHC, albumin, and total protein at the indicated time points in the study from the respective Baseline values.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "grams per liter", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "87"}]}], "classes": [{"title": "MCHC, Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.00", "lowerLimit": "-30.00", "upperLimit": "27.00"}]}]}, {"title": "MCHC, Week 28, Adj O, n=21", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "-18.00", "upperLimit": "26.00"}]}]}, {"title": "MCHC, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.00", "lowerLimit": "-31.00", "upperLimit": "24.00"}]}]}, {"title": "MCHC, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "-25.00", "upperLimit": "15.00"}]}]}, {"title": "Albumin, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-5.00", "upperLimit": "7.00"}]}]}, {"title": "Albumin, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.00", "lowerLimit": "-8.00", "upperLimit": "3.00"}]}]}, {"title": "Albumin, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-6.00", "upperLimit": "6.00"}]}]}, {"title": "Albumin, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-9.00", "upperLimit": "6.00"}]}]}, {"title": "Total Protein, Week 15, WD, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "lowerLimit": "-13.0", "upperLimit": "8.0"}]}]}, {"title": "Total Protein, Week 28, WD, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.00", "lowerLimit": "-11.0", "upperLimit": "3.0"}]}]}, {"title": "Total Protein, Week 28, WD, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "lowerLimit": "-15.0", "upperLimit": "6.0"}]}]}, {"title": "Total Protein, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "lowerLimit": "-15.0", "upperLimit": "7.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCH at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "picograms", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}]}], "classes": [{"title": "Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "lowerLimit": "-3.30", "upperLimit": "2.60"}]}]}, {"title": "Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "lowerLimit": "-1.20", "upperLimit": "1.60"}]}]}, {"title": "Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "lowerLimit": "-2.30", "upperLimit": "1.40"}]}]}, {"title": "Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "lowerLimit": "-1.90", "upperLimit": "3.50"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points in the the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCV at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Femtoliters", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}]}], "classes": [{"title": "Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-7.00", "upperLimit": "9.00"}]}]}, {"title": "Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.00", "lowerLimit": "-7.00", "upperLimit": "5.00"}]}]}, {"title": "Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "-9.00", "upperLimit": "7.00"}]}]}, {"title": "Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-4.00", "upperLimit": "12.00"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of RBC count at the indicated time points in the study from the Baseline value. Change from baseline is measured as the number of red blood cells x 10\\^12 per liter.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Tera (10^12) cells per liter", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}]}], "classes": [{"title": "Week 15, Adj M, n=85", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "lowerLimit": "-0.90", "upperLimit": "0.40"}]}]}, {"title": "Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "lowerLimit": "-0.80", "upperLimit": "0.10"}]}]}, {"title": "Week 28, Mono, n=55", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "lowerLimit": "-0.70", "upperLimit": "0.40"}]}]}, {"title": "Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.50", "upperLimit": "1.00"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Alkaline Phosphatase (Alk P), Alanine Amino Transferase (Ala AT), and Aspartate Amino Transferase (Asp AT) at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of Alk P, Ala AT, and Asp AT at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "International units per liter", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}]}], "classes": [{"title": "Alk P, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "-86.0", "upperLimit": "141.00"}]}]}, {"title": "Alk P, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "lowerLimit": "-72.0", "upperLimit": "20.0"}]}]}, {"title": "Alk P, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.0", "lowerLimit": "-118.0", "upperLimit": "49.0"}]}]}, {"title": "Alk P, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.00", "lowerLimit": "-90.0", "upperLimit": "90.00"}]}]}, {"title": "Ala-AT Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.00", "lowerLimit": "-30.0", "upperLimit": "71.0"}]}]}, {"title": "Ala-AT, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "lowerLimit": "-10.0", "upperLimit": "23.0"}]}]}, {"title": "Ala-AT, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "lowerLimit": "-32.0", "upperLimit": "55.0"}]}]}, {"title": "Ala-AT, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "lowerLimit": "-20.0", "upperLimit": "7.0"}]}]}, {"title": "Asp-AT, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "lowerLimit": "-19.0", "upperLimit": "47.0"}]}]}, {"title": "Asp-AT, Week 28, WD, n=32", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.0", "lowerLimit": "-34.0", "upperLimit": "7.0"}]}]}, {"title": "Asp-AT, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "lowerLimit": "-13.0", "upperLimit": "18.0"}]}]}, {"title": "Asp-AT, Week 28, Mono, n=60", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-15.0", "upperLimit": "17.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Direct Bilirubin (DB), Total Bilirubin (TB), and Creatinine at the Indicated Time Points in the Study", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of DB, TB, and creatinine at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "micromoles (\u00b5mol) per liter", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}]}], "classes": [{"title": "DB, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-1.7", "upperLimit": "6.8"}]}]}, {"title": "DB, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-3.4", "upperLimit": "1.7"}]}]}, {"title": "DB, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-1.7", "upperLimit": "12.0"}]}]}, {"title": "DB, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-1.7", "upperLimit": "1.7"}]}]}, {"title": "TB, Week 15, Adj M, n=88", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-8.6", "upperLimit": "15.4"}]}]}, {"title": "TB, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-3.4", "upperLimit": "1.7"}]}]}, {"title": "TB, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "lowerLimit": "-8.6", "upperLimit": "12.0"}]}]}, {"title": "TB, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-3.4", "upperLimit": "5.1"}]}]}, {"title": "Creatinine, Week 15, Adj M, n=88", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.8", "lowerLimit": "-17.7", "upperLimit": "53.0"}]}]}, {"title": "Creatinine, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.8", "lowerLimit": "0.0", "upperLimit": "203.3"}]}]}, {"title": "Creatinine, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.8", "lowerLimit": "-17.7", "upperLimit": "53.0"}]}]}, {"title": "Creatinine, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-17.7", "upperLimit": "17.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Glucose, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points", "description": "The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of cholesterol, HDL cholesterol, LDL cholesterol, glucose, potassium, sodium, triglycerides, and urea/BUN at the indicated time points in the study from the Baseline value.", "populationDescription": "Safety Population. Only those participants with both a baseline and post-baseline value were analyzed.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "millimoles (mmol) per liter", "timeFrame": "Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)", "groups": [{"id": "OG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "87"}]}], "classes": [{"title": "Cholesterol, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-1.7", "upperLimit": "1.7"}]}]}, {"title": "Cholesterol, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-2.2", "upperLimit": "0.9"}]}]}, {"title": "Cholesterol, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "lowerLimit": "-2.5", "upperLimit": "1.2"}]}]}, {"title": "Cholesterol, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-3.5", "upperLimit": "1.0"}]}]}, {"title": "HDL Cholesterol, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "lowerLimit": "-1.0", "upperLimit": "0.6"}]}]}, {"title": "HDL Cholesterol, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0", "lowerLimit": "-0.4", "upperLimit": "0.6"}]}]}, {"title": "HDL Cholesterol, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-0.7", "upperLimit": "0.7"}]}]}, {"title": "HDL Cholesterol, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "lowerLimit": "-0.9", "upperLimit": "0.4"}]}]}, {"title": "LDL Cholesterol, Week 15, Adj M, n=86", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0", "lowerLimit": "-1.1", "upperLimit": "1.2"}]}]}, {"title": "LDL Cholesterol, Week 28, Adj O, n=19", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "lowerLimit": "-1.9", "upperLimit": "1.1"}]}]}, {"title": "LDL Cholesterol, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-1.8", "upperLimit": "1.6"}]}]}, {"title": "LDL Cholesterol, Week 28, WD, n=32", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-0.8", "upperLimit": "1.7"}]}]}, {"title": "Glucose, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-5.8", "upperLimit": "5.3"}]}]}, {"title": "Glucose, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "lowerLimit": "-6.7", "upperLimit": "6.7"}]}]}, {"title": "Glucose, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "lowerLimit": "-3.6", "upperLimit": "6.4"}]}]}, {"title": "Glucose, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "lowerLimit": "-5.2", "upperLimit": "4.2"}]}]}, {"title": "Potassium, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-1.2", "upperLimit": "1.1"}]}]}, {"title": "Potassium, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-0.7", "upperLimit": "1.2"}]}]}, {"title": "Potassium, Week 28, Mono, n=60", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-1.3", "upperLimit": "1.2"}]}]}, {"title": "Potassium, Week 28, WD, n=32", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-1.0", "upperLimit": "0.9"}]}]}, {"title": "Sodium, Week 15, Adj M, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-4.0", "upperLimit": "6.0"}]}]}, {"title": "Sodium, Week 28, Adj O, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "lowerLimit": "-7.0", "upperLimit": "4.0"}]}]}, {"title": "Sodium, Week 28, Mono, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "lowerLimit": "-5.0", "upperLimit": "9.0"}]}]}, {"title": "Sodium, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "lowerLimit": "-3.0", "upperLimit": "7.0"}]}]}, {"title": "Triglyceride, Week 28, WD, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "lowerLimit": "-2.3", "upperLimit": "0.9"}]}]}, {"title": "Triglyceride, Week 28, WD, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-1.7", "upperLimit": "1.6"}]}]}, {"title": "Triglyceride, Week 28, WD, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "lowerLimit": "-1.9", "upperLimit": "1.1"}]}]}, {"title": "Triglyceride, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "lowerLimit": "-4.6", "upperLimit": "1.1"}]}]}, {"title": "Urea/BUN, Week 28, WD, n=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-10.4", "upperLimit": "5.4"}]}]}, {"title": "Urea/BUN, Week 28, WD, n=20", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "lowerLimit": "-2.1", "upperLimit": "13.2"}]}]}, {"title": "Urea/BUN, Week 28, WD, n=61", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-6.4", "upperLimit": "6.8"}]}]}, {"title": "Urea/BUN, Week 28, WD, n=33", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "lowerLimit": "-4.3", "upperLimit": "3.6"}]}]}]}, {"type": "SECONDARY", "title": "Serum LTG Concentrations at Different LTG Doses Based on the Concomitant AED Groups: Neutral (Without Known Enzyme-inducing AED [EIAED], Valproate [VPA]) With EIAED, and With VPA", "description": "The blood samples were collected at the specified study visits; however, serum LTG concentrations were summarized by dose regimen, not by study week. The serum was assayed for LTG using an approved method under the management of Worldwide Bioanalysis, GlaxoSmithKline.", "populationDescription": "Safety Population. Participants with missing data were not analyzed. Not all participants received all doses at each blood draw; therefore, participants were only analyzed for the dose received at blood draw.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Micrograms per milliliter", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28", "typeUnitsAnalyzed": "serum concentrations", "denomUnitsSelected": "serum concentrations", "groups": [{"id": "OG000", "title": "LTG-XR + Neutral", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (does not include VPA or EIAEDs), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}, {"id": "OG001", "title": "LTG-XR + EIAEDs", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-w Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (included EIAEDs), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}, {"id": "OG002", "title": "LTG-XR + VPA", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-w Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (included VPA), followed by an 8-w Adjunctive Maintenance Phase: LTG-XR tablets administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "12"}]}, {"units": "serum concentrations", "counts": [{"groupId": "OG000", "value": "439"}, {"groupId": "OG001", "value": "243"}, {"groupId": "OG002", "value": "54"}]}], "classes": [{"title": "12.5 mg, n=0, 0, 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No dose was given for this regimen."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No dose was given for this regimen."}, {"groupId": "OG002", "value": "0.957", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No full range is provided for the median value because only one participant was analyzed."}]}]}, {"title": "25 mg, n=0, 0, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No dose was given for this regimen."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No dose was given for this regimen."}, {"groupId": "OG002", "value": "1.362", "lowerLimit": "0.817", "upperLimit": "2.885"}]}]}, {"title": "50 mg, n=30, 2, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.281", "lowerLimit": "0.437", "upperLimit": "3.491"}, {"groupId": "OG001", "value": "0.731", "lowerLimit": "0.727", "upperLimit": "0.734"}, {"groupId": "OG002", "value": "2.972", "lowerLimit": "0.937", "upperLimit": "3.553"}]}]}, {"title": "100 mg, n=40, 32, 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.425", "lowerLimit": "0.717", "upperLimit": "5.825"}, {"groupId": "OG001", "value": "1.165", "lowerLimit": "0.442", "upperLimit": "4.254"}, {"groupId": "OG002", "value": "4.723", "lowerLimit": "3.870", "upperLimit": "6.419"}]}]}, {"title": "150 mg, n=11, 0, 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.653", "lowerLimit": "2.514", "upperLimit": "9.693"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}, {"groupId": "OG002", "value": "6.829", "lowerLimit": "3.549", "upperLimit": "10.804"}]}]}, {"title": "200 mg, n=74, 22, 25", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.499", "lowerLimit": "1.449", "upperLimit": "12.926"}, {"groupId": "OG001", "value": "1.583", "lowerLimit": "0.455", "upperLimit": "3.542"}, {"groupId": "OG002", "value": "5.350", "lowerLimit": "3.301", "upperLimit": "13.750"}]}]}, {"title": "225 mg, n=3, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.631", "lowerLimit": "4.815", "upperLimit": "5.642"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}]}]}, {"title": "250 mg, n=18, 11, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.059", "lowerLimit": "2.329", "upperLimit": "10.969"}, {"groupId": "OG001", "value": "4.073", "lowerLimit": "2.184", "upperLimit": "8.768"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}]}]}, {"title": "300 mg, n=193, 5, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.493", "lowerLimit": "1.620", "upperLimit": "13.335"}, {"groupId": "OG001", "value": "2.837", "lowerLimit": "1.898", "upperLimit": "3.558"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}]}]}, {"title": "350 mg, n=0, 3, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No dose was given for this regimen."}, {"groupId": "OG001", "value": "4.084", "lowerLimit": "3.794", "upperLimit": "4.165"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}]}]}, {"title": "400 mg, n=19, 46, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.322", "lowerLimit": "2.899", "upperLimit": "13.843"}, {"groupId": "OG001", "value": "4.012", "lowerLimit": "1.459", "upperLimit": "9.675"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}]}]}, {"title": "450 mg, n=0, 1, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No dose was given for this regimen."}, {"groupId": "OG001", "value": "2.975", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No full range is provided for the median value because only one participant was analyzed."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}]}]}, {"title": "500 mg, n=51, 121, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.994", "lowerLimit": "0.931", "upperLimit": "13.412"}, {"groupId": "OG001", "value": "3.974", "lowerLimit": "0.905", "upperLimit": "11.451"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "No participants were analyzed in this group at this dose level."}]}]}]}, {"type": "SECONDARY", "title": "Apparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA", "description": "Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. Clearance is defined as the volume of LTG per unit time eliminated from serum. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to Clinical Pharmacokinetics Modelling and Simulation, Clinical Pharmacology, and Discovery Medicine (CPDM) by Clinical Data Management as NONMEM compatible .csv files.", "populationDescription": "Safety Population. Participants with missing data were not analyzed. Not all participants received all doses at each blood draw; therefore, participants were only analyzed for the dose received at blood draw.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters per hour", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28", "groups": [{"id": "OG000", "title": "LTG-XR + Neutral", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (does not include VPA or EIAEDs), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}, {"id": "OG001", "title": "LTG-XR + EIAEDs", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-w Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (included EIAEDs), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}, {"id": "OG002", "title": "LTG-XR + VPA", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-w Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (included VPA), followed by an 8-w Adjunctive Maintenance Phase: LTG-XR tablets administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.91", "lowerLimit": "1.73", "upperLimit": "2.09"}, {"groupId": "OG001", "value": "2.07", "lowerLimit": "1.69", "upperLimit": "2.46"}, {"groupId": "OG002", "value": "-0.698", "lowerLimit": "-0.96", "upperLimit": "-0.441"}]}]}]}, {"type": "SECONDARY", "title": "Apparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA", "description": "Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. V/F is defined as the apparent volume in which a drug is distributed immediately after it has been injected intravenously and equilibrated between plasma and the surrounding tissues. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.", "populationDescription": "Safety Population. Participants with missing data were not analyzed. Not all participants received all doses at each blood draw; therefore, participants were only analyzed for the dose received at blood draw.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28", "groups": [{"id": "OG000", "title": "LTG-XR + Neutral, EIAEDs, and VPA", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (included VPA and EIAEDs), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.8", "lowerLimit": "7.40", "upperLimit": "46.6"}]}]}]}, {"type": "SECONDARY", "title": "Absorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA", "description": "Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. KA is defined as the rate at which a drug enters the body after administration. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.", "populationDescription": "Safety Population. Participants with missing data were not analyzed. Not all participants received all doses at each blood draw; therefore, participants were only analyzed for the dose received at blood draw.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "1/h", "timeFrame": "Weeks 4, 7, 11, 15, 20, 24, and 28", "groups": [{"id": "OG000", "title": "LTG-XR + Neutral, EIAEDs, and VPA", "description": "LTG-XR tablets (25, 50, 100, and 200 mg) were administered OD in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant AED (included VPA and EIAEDs), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0325", "lowerLimit": "0.0105", "upperLimit": "0.0549"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "LTG-XR Tablets", "description": "LTG-XR tablets (25, 50, 100, and 200 milligrams \\[mg\\]) administered once a day (OD) in the 7-week (w) Dose-Escalation Phase and titrated to target doses of 300, 500, or 200 mg/day for participants (par.) depending on their concomitant antiepileptic drug (AED), followed by an 8-w Adjunctive Maintenance Phase in which LTG-XR tablets were administered OD at the target dose. Par. on a single concomitant AED who converted to LTG-XR monotherapy (based on investigator's judgment) entered the 5-w Conversion Phase, followed by an 8-w Monotherapy Phase, whereas par. who did not transition to monotherapy entered the 13-w Adjunctive Optimization Phase. At the end of the study, par. entered the 2- to 5-w Taper/Follow-Up Phase, in which par. either switched to commercial LTG (received same total daily dose of commercial LTG in 2 divided doses \\[BID\\]) or did not switch to commercial LTG (current dose was reduced by approximately one-fourth per week) with a final visit 2 weeks after last LTG-XR dose.", "seriousNumAffected": 22, "seriousNumAtRisk": 121, "otherNumAffected": 98, "otherNumAtRisk": 121}], "seriousEvents": [{"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 121}]}, {"term": "Ataxia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 121}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 121}]}, {"term": "Status epilepticus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 121}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Balance disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Grand mal convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Lethargy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Lower gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Small cell lung cancer stage unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Toxic encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}]}], "otherEvents": [{"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 31, "numAtRisk": 121}]}, {"term": "Balance disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 121}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 121}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 121}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 121}]}, {"term": "Fatigue", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 121}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 121}]}, {"term": "All rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 121}]}, {"term": "Ataxia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 121}]}, {"term": "Nasopharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 121}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 121}]}, {"term": "Pain In extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 121}]}, {"term": "Gait disturbance", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 121}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 121}]}, {"term": "Arthralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 121}]}, {"term": "Confusional state", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 121}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 121}]}, {"term": "Decreased appetite", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 121}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 121}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 121}]}, {"term": "Skin laceration", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 121}]}, {"term": "Urinary tract infection", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 121}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Puerto Rico", "United Kingdom"]}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M15452", "name": "Seizures", "relevance": "LOW"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077213", "term": "Lamotrigine"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}], "browseLeaves": [{"id": "M1701", "name": "Lamotrigine", "asFound": "Muscle strength", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}